NCT03910673View on ClinicalTrials.gov

Intravenous Fosfomycin Pharmacokinetics Study

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

December 17, 2020

Study Completion Date

December 17, 2020

Conditions
Bacterial InfectionMultiple-drug ResistancePathogen Resistance
Interventions
DRUG

Fosfomycin disodium

Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.

Trial Locations (1)

27704

Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03910673 - Intravenous Fosfomycin Pharmacokinetics Study | Biotech Hunter | Biotech Hunter